Aurinia Pharmaceuticals Inc. announced that for fiscal year 2022, the Company is providing net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150% to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.45 USD | -1.80% | -0.18% | -39.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.38% | 792M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022